Phelan, RW,Barret, M,Cotter, PD,O'Connor, PM,Chen, R,Morrissey, JP,Dobson, ADW,O'Gara, F,Barbosa, TM

2013

June

Marine Drugs

Subtilomycin: A New Lantibiotic from Bacillus subtilis Strain MMA7 Isolated from the Marine Sponge Haliclona simulans

Validated

Altmetric: 2 ()

antimicrobial subtilomycin lantibiotic marine sponge Bacillus subtilis ANTIMICROBIAL ACTIVITIES POSTTRANSLATIONAL MODIFICATIONS APLYSINA-AEROPHOBA SPORE-FORMERS BIOSYNTHESIS BACTERIA IDENTIFICATION ANTIBIOTICS COMMUNITIES WATERS

11

1878

1898

Bacteriocins are attracting increased attention as an alternative to classic antibiotics in the fight against infectious disease and multidrug resistant pathogens. Bacillus subtilis strain MMA7 isolated from the marine sponge Haliclona simulans displays a broad spectrum antimicrobial activity, which includes Gram-positive and Gram-negative pathogens, as well as several pathogenic Candida species. This activity is in part associated with a newly identified lantibiotic, herein named as subtilomycin. The proposed biosynthetic cluster is composed of six genes, including protein-coding genes for LanB-like dehydratase and LanC-like cyclase modification enzymes, characteristic of the class I lantibiotics. The subtilomycin biosynthetic cluster in B. subtilis strain MMA7 is found in place of the sporulation killing factor (skf) operon, reported in many B. subtilis isolates and involved in a bacterial cannibalistic behaviour intended to delay sporulation. The presence of the subtilomycin biosynthetic cluster appears to be widespread amongst B. subtilis strains isolated from different shallow and deep water marine sponges. Subtilomycin possesses several desirable industrial and pharmaceutical physicochemical properties, including activity over a wide pH range, thermal resistance and water solubility. Additionally, the production of the lantibiotic subtilomycin could be a desirable property should B. subtilis strain MMA7 be employed as a probiotic in aquaculture applications.

10.3390/md11061878